This study of Esteve and coworkers unveils SFRP-1 as a crucial player in AD pathogenesis through the inhibition of ADAM10, but other studies indicate that SFRP act as Wnt antagonist sequestering Wnt ligands in the extracellular space (Folke et al., 2018), therefore, these effects also could be due, almost in part, to the inhibition of Wnt signaling. Here, SFRP1 is linked to Alzheimer disease.